(Total Views: 648)
Posted On: 10/20/2020 10:21:05 AM
Post# of 1460
CTAD- AVXL November 6 (found at the swamp)
11.02 a.m LB25 - ANAVEX®2-73 (blarcamesine) Currently in Phase 2b/3 Early Alzheimer’s Disease (AD): Analysis of Cognitive Outcome
Measures Relevant in AD of Double-blind, Multicenter, Placebo-controlled Phase 2 Clinical Trial in 132 Patients with Parkinson’s
Disease Dementia
Dag Aarsland (1), Jaime Kulisevsky Bojarski (2), Mohammad Afshar (3), Coralie Williams (3), Frederic Parmentier (3), Martin
Kindermans (3), Tayo Fadiran (4), Andy Mattai (4), Christopher U Missling (4), Walter E Kaufmann (4)
(1)King’s College - London (United Kingdom); (2)University of Barcelona - Barcelona (Spain); (3)Ariana Pharma - Paris (France); (4)Anavex Life
Sciences - New York, NY (United States)
Friday, November 6
https://www.ctad-alzheimer.com/files/files/DI..._19oct.pdf
11.02 a.m LB25 - ANAVEX®2-73 (blarcamesine) Currently in Phase 2b/3 Early Alzheimer’s Disease (AD): Analysis of Cognitive Outcome
Measures Relevant in AD of Double-blind, Multicenter, Placebo-controlled Phase 2 Clinical Trial in 132 Patients with Parkinson’s
Disease Dementia
Dag Aarsland (1), Jaime Kulisevsky Bojarski (2), Mohammad Afshar (3), Coralie Williams (3), Frederic Parmentier (3), Martin
Kindermans (3), Tayo Fadiran (4), Andy Mattai (4), Christopher U Missling (4), Walter E Kaufmann (4)
(1)King’s College - London (United Kingdom); (2)University of Barcelona - Barcelona (Spain); (3)Ariana Pharma - Paris (France); (4)Anavex Life
Sciences - New York, NY (United States)
Friday, November 6
https://www.ctad-alzheimer.com/files/files/DI..._19oct.pdf
(1)
(0)
